CD40 Ligand in CLL Pathogenesis and Therapy

References

• Kipps T J, Carson D A. Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood 1993; 81: 2475–87
   PubMed Web of Science ®Google Scholar
• Caligaris‐Cappio F. B‐chronic lymphocytic leukemia: a malignancy of anti‐self B cells. Blood 1996; 87: 2615–20
   PubMed Web of Science ®Google Scholar
• Kantor A. A new nomenclature for B cells. Immunol Today 1991; 12: 388
   PubMedGoogle Scholar
• Hardy R R, Li Y S, Hayakawa K. Distinctive developmental origins and specificities of the CD5+ B‐cell subset. Semin Immunol 1996; 8: 37–44
   PubMedGoogle Scholar
• Casali P, Burastero S E, Nakamura M, Inghirami G, Notkins A L. Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu‐1+ B‐cell subset. Science 1987; 236: 77–81
   PubMed Web of Science ®Google Scholar
• Diaw L, Magnac C, F'ritsch O, Buckle M, Alzari P M, Dighiero G. Structural and affinity studies of IgM polyreactive natural autoantibodies. J Immunol 1997; 158: 968–76
   PubMed Web of Science ®Google Scholar
• Hayakawa K, Asano M, Shinton S A, Gui M, Allman D, Stewart C L, Silver J, Hardy R R. Positive selection of natural autoreactive B cells. Science 1999; 285: 113–6
   PubMed Web of Science ®Google Scholar
• Durandy A, Thuillier L, Forveille M, Fischer A. Phenotypic and functional characteristics of human newborns' B lymphocytes. J Immunol 1990; 144: 60–5
   PubMed Web of Science ®Google Scholar
• Kasaian M T, Casali P. Autoimmunity‐prone B‐1 (CD5 B) cells, natural antibodies and self recognition. Autoimmunity 1993; 15: 315–29
   PubMed Web of Science ®Google Scholar
• Diehl L F, Ketchum L H. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, purered cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 1998; 25: 80–97
   PubMed Web of Science ®Google Scholar
• Pritsch O, Maloum K, Dighiero G. Basic biology of autoimmune phenomena in chronic lymphocytic leukemia. Semin Oncol 1998; 25: 34–41
   PubMed Web of Science ®Google Scholar
• Fu S M, Chiorazzi N, Kunkel H G, Halper J P, Harris S R. Induction of in vitro differentiation and immunoglobulin synthesis of human leukemic B lymphocytes. Journal of Experimental Medicine 1978; 148: 1570–8
   PubMed Web of Science ®Google Scholar
• Fu S M, Chiorazzi N, Kunkel H G. Differentiation capacity and other properties of the leukemic cells of chronic lymphocytic leukemia. Immunological Reviews 1979; 48: 23–44
   PubMed Web of Science ®Google Scholar
• Johnstone A P, Jensenius J C, Millard R E, Hudson L. Mitogen‐stimulated immunoglobulin production by chronic lymphocytic leukaemic lymphocytes. Clinical. & Experimental Immunology 1982; 47: 697–705
   PubMed Web of Science ®Google Scholar
• Sthoeger Z M, Wakai M, Tse D B, Vinciguerra V P, Allen S L, Budman D R, Lichtman S M, Schulman P, Weiselberg L R, Chiorazzi N. Production of autoantibodies by CD5‐expressing B lymphocytes from patients with chronic lymphocytic leukemia. Journal of Experimental Medicine 1989; 169: 255–68
   PubMed Web of Science ®Google Scholar
• Schroeder H W, Jr, Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today 1994; 15: 288–94
   PubMedGoogle Scholar
• Fais F, Sellars B, Ghiotto F, Yan X J, Dono M, Allen S L, Budman D, Dittmar K, Kolitz J, Lichtman S M, Schulman P, Schuster M, Vinciguerra V P, Rai K, Stevenson F K, Gregersen P K, Ferrarini M, Chiorazzi N. Examples of in vivo isotype class switching in IgM+ chronic lymphocytic leukemia B cells. J Clin Invest 1996; 98: 1659–66
   PubMed Web of Science ®Google Scholar
• Malisan F, Fluckiger A C, Ho S, Guret C, Banchereau J, Martinez‐Valdez H. B‐chronic lymphocytic leukemias can undergo isotype switching in vivo and can be induced to differentiate and switch in vitro. Blood 1996; 87: 717–24
   PubMed Web of Science ®Google Scholar
• Ledbetter J A, Shu G, Gallagher M, Clark E A. Augmentation of normal and malignant B cell proliferation by monoclonal antibody to the B cell‐specific antigen BP50 (CDW40). Journal of Immunology 1987; 138: 788–94
   PubMed Web of Science ®Google Scholar
• Stamenkovic I, Clark E A, Seed B. A B‐lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO Journal 1989; 8: 1403–10
   PubMed Web of Science ®Google Scholar
• van Kooten C, Banchereau J. Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol 1997; 9: 330–7
   PubMed Web of Science ®Google Scholar
• Noelle R J, Roy M, Shepherd D M, Stamenkovic I, Ledbetter J A, Aruffo A. A 39‐kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci USA 1992; 89: 6550–4
   PubMed Web of Science ®Google Scholar
• Graf D, Korthauer U, Mages H W, Senger G, Kroczek R A. Cloning of TRAP, a ligand for CD40 on human T cells. Eur J Immunol 1992; 22: 3191–4
   PubMed Web of Science ®Google Scholar
• Lederman S, Yellin M J, Krichevsky A, Belko J, Lee J J, Chess L. Identification of a novel surface protein on activated CD4+ T cells that induces contact‐dependent B cell differentiation (help). Journal of Experimental Medicine 1992; 175: 1091–101
   PubMed Web of Science ®Google Scholar
• Spriggs M K, Armitage R J, Strockbine L, Clifford K N, Macduff B M, Sato T A, Maliszewski C R, Fanslow W C. Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion. J Exp Med 1992; 176: 1543–50
   PubMed Web of Science ®Google Scholar
• Liu Y J, Joshua D E, Williams G T, Smith C A, Gordon J, MacLennan I C. Mechanism of antigen‐driven selection in germinal centres. Nature 1989; 342: 929–31
   PubMed Web of Science ®Google Scholar
• Banchereau J, de Paoli P, Valle A, Garcia E, Rousset F. Long‐term human B cell lines dependent on inter‐leukin‐4 and antibody to CD40. Science 1991; 251: 70–2
   PubMed Web of Science ®Google Scholar
• Lederman S, Yellin M J, Cleary A M, Pernis A, Inghirami G, Cohn L E, Covey L R, Lee J J, Rothman P, Chess L. T‐BAM/CD40‐L on helper T lymphocytes augments lymphokine‐induced B cell Ig isotype switch recombination and rescues B cells from programmed cell death. Journal of Immunology 1994; 152: 2163–71
   PubMed Web of Science ®Google Scholar
• Ranheim E A, Kipps T J. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40‐dependent signal. J Exp Med 1993; 177: 925–35
   PubMed Web of Science ®Google Scholar
• Saeland S, Duven V, Moreau I, Banchereau J. Human B cell precursors proliferate and express CD23 after CD40 ligation. Journal of Experimental Medicine 1993; 178: 113–20
   PubMed Web of Science ®Google Scholar
• Rothstein T L, Wang J K, Panka D J, Foote L C, Wang Z, Stanger B, Cui H, Ju S T, Marshak‐Rothstein A. Protection against Fas‐dependent Thl‐mediated apoptosis by antigen receptor engagement in B cells. Nature 1995; 374: 163–5
   PubMed Web of Science ®Google Scholar
• Schattner E J, Elkon K B, Yoo D H, Tumang J, Krammer P H, Crow M K, Friedman S M. CD40 ligation induces Apo‐1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo‐1/as pathway. Journal of Experimental Medicine 1995; 182: 1557–65
   PubMed Web of Science ®Google Scholar
• Gamone P, Neidhardt E M, Garcia E, Galibert L, van Kooten C, Banchereau J. Fas ligation induces apoptosis of CD40‐activated human B lymphocytes. Journal of Experimental Medicine 1995; 182: 1265–73
   PubMed Web of Science ®Google Scholar
• Lalmanach‐Girard A C, Chiles T C, Parker D C, Rothstein T L. T cell‐dependent induction of NF‐kappa B in B cells. J Exp Med 1993; 177: 1215–9
   PubMed Web of Science ®Google Scholar
• Berberich I, Shu G L, Clark E A. Cross‐linking CD40 on B cells rapidly activates nuclear factor‐kappa B. J Immunol 1994; 153: 4357–66
   PubMed Web of Science ®Google Scholar
• Grumont R J, Rourke I J, Gerondakis S. Rel‐dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation‐induced apoptosis. Genes Dev 1999; 13: 400–11
   PubMed Web of Science ®Google Scholar
• Dighiero G, Kipps T, Schroeder H W, Chiorazzi N, Stevenson F, Silberstein L E, Caligaris‐Cappio F, Ferrarini M. What is the CLL B‐lymphocyte?. Leuk Lymphoma 1996; 2: 13–39
   Web of Science ®Google Scholar
• Andreeff M, Darzynkiewicz Z, Sharpless T K, Clarkson B D, Melamed M R. Discrimination of human leukemia subtypes by flow cytometric analysis of cellular DNA and RNA. Blood 1980; 55: 282–93
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Stein H, Banks P M, Chan J K, Cleary M L, Delsol G, De Wolf‐Peeters C, Falini B, Gatter K C, Grogan T M, Isaacson P G, Knowles D M, Mason D Y, Muller‐Hermelink H K, Pileri S A, Piris M A, Ralfkiaer E, Warnke R A. A revised European‐American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–92
   PubMed Web of Science ®Google Scholar
• Gregory C D, Tursz T, Edwards C F, Tetaud C, Talbot M, Caillou B, Rickinson A B, Lipinski M. Identification of a subset of normal B cells with a Burkitt's lymphoma (BL)‐like phenotype. Journal of Immunology 1987; 139: 313–8
   PubMed Web of Science ®Google Scholar
• Klein G. Epstein‐Bm virus strategy in normal and neoplastic B cells. Cell 1994; 77: 791–3
   PubMed Web of Science ®Google Scholar
• Schattner El, Mascarenhas J, Reyfman I, Koshy M, Woo C, Friedman S M, Crow M K. Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T‐cell type costimulatory capacity. Blood 1998; 91: 2689–97
   PubMed Web of Science ®Google Scholar
• Trentin L, Zambello R, Sancetta R, Facco M, Cerutti A, Perin A, Siviero M, Basso U, Bortolin M, Adami F, Agostini C, Semenzato G. B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules. Cancer Research 1997; 57: 4940–7
   PubMed Web of Science ®Google Scholar
• Clodi K, Asgary Z, Zhao S, Kliche K ‐O, Cabanillas F, Andreeff M, Younes A. Coexpression of CD40 and CD40 ligand in B‐cell lymphoma cells. British Journal of Haematology 1998; 103: 270–5
   PubMed Web of Science ®Google Scholar
• Wasil T, Damle R N, Allen S L, Buchbinder A, Kittmar K, Kolitz J, Lichtman S M, Schulman P, Vinciguerra V, Rai K R, Chiorazzi N. Overexpression of CD40L on the b and T cells of chronic lymphocytic leukemia patients with autoimmune phenomena, Proceedings of ASCO. May, 1998. American Society of Clinical Oncology, Vol. 17
   Google Scholar
• Wykes M, Poudrier J, Lindstedt R, Gray D. Regulation of cytoplasmic, surface and soluble forms of CD40 ligand in mouse B cells. Eur J Immunol 1998; 28: 548–59
   PubMed Web of Science ®Google Scholar
• Wang D, Freeman G J, Levine H, Ritz J, Robertson M J. Role of the CD40 and CD95 (APO‐1/Fas) antigens in the apoptosis of human B‐cell malignancies. Br J Haematol 1997; 97: 409–17
   PubMed Web of Science ®Google Scholar
• Kamihira S, Yamada Y, Hirakata Y, Tsuruda K, Sugahara K, Tomonaga M, Maeda T, Tsukasaki K, Atogami S, Kobayashi N. Quantitative characterization and potential function of membrane Fas/APO‐1 (CD95) receptors on leukaemic cells from chronic B and T lymphoid leukaemias. Br J Haematol 1997; 99: 858–65
   PubMed Web of Science ®Google Scholar
• Hostager B S, Hsing Y, Harms D E, Bishop G A. Different CD40‐mediated signaling events require distinct CD40 structural features. J Immunol 1996; 157: 1047–53
   PubMed Web of Science ®Google Scholar
• Hsing Y, Bishop G A. Requirement for nuclear factor‐kappaB activation by a distinct subset of CD40‐mediated effector functions in B lymphocytes. J Immunol 1999; 162: 2804–11
   PubMed Web of Science ®Google Scholar
• Vakkalanka R K, Woo C, Kirou K A, Koshy M, Berger D, Crow M K. Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthritis Rheum 1999; 42: 871–81
   PubMed Web of Science ®Google Scholar
• Grammer A C, Bergman M C, Miura Y, Fujita K, Davis L S, Lipsky P E. The CD40 ligand expressed by human B cells costimulates B cell responses. Journal of Immunology 1995; 154: 4996–5010
   PubMed Web of Science ®Google Scholar
• Carbone E, Ruggiero G, Terrazzano G, Palomba C, Manzo C, Fontana S, Spits H, Kame K, Zappacosta S. A new mechanism of NK cell cytotoxicity activation: the CD40‐CD40 ligand interaction. J Exp Med 1997; 185: 2053–60
   PubMed Web of Science ®Google Scholar
• Gauchat J F, Henchoz S, Mazzei G, Aubry J P, Brunner T, Blasey H, Life P, Talabot D, Flores‐Romo L, Thompson J, et al. Induction of human IgE synthesis in B cells by mast cells and basophils. Nature 1993; 365: 340–3
   PubMed Web of Science ®Google Scholar
• Mach F, Schonbeck U, Sukhova G K, Bourcier T, Bonnefoy J Y, Pober J S, Libby P. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40‐CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997; 94: 1931–6
   PubMed Web of Science ®Google Scholar
• Henn V, Slupsky J R, Grafe M, Anagnostopoulos I, Forster R, Muller‐Berghaus G, Kroczek R A. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591–4
   PubMed Web of Science ®Google Scholar
• Roy M, Waldschmidt T, Aruffo A, Ledbetter J A, Noelle R J. The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells. J Immunol 1993; 151: 2497–510
   PubMed Web of Science ®Google Scholar
• Pietravalle F, Lecoanet‐Henchoz S, Blasey H, Aubry J P, Elson G, Edgerton M D, Bonnefoy J Y, Gauchat J F. Human native soluble CD40L is a biologically active trimer, processed inside microsomes. J Biol Chem 1996; 271: 5965–7
   PubMed Web of Science ®Google Scholar
• Graf D, Muller S, Korthauer U, van Kooten C, Weise C, Kroczek R A. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol 1995; 25: 1749–54
   PubMed Web of Science ®Google Scholar
• Black R A, Rauch C T, Kozlosky C J, Peschon J J, Slack J L, Wolfson M F, Castner B J, Stocking K L, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley K A, Gerhart M, Davis R, Fitzner J N, Johnson R S, Paxton R J, March C J, Cerretti D P. A metalloproteinase disintegrin that releases tumour‐necrosis factor‐alpha from cells. Nature 1997; 385: 729–33
   PubMed Web of Science ®Google Scholar
• Moss M L, Jin S L, Milla M E, Bickett D M, Burkhart W, Carter H L, Chen W J, Clay W C, Didsbury J R, Hassler D, Hoffman C R, Kost T A, Lambert M H, Leesnitzer M A, McCauley P, McGeehan G, Mitchell J, Moyer M, Pahel G, Rocque W, Overton L K, Schoenen F, Seaton T, Su J L, Becherer J D, et al. Cloning of a disintegrin metalloproteinase that processes precursor tumour‐necrosis factor‐alpha. Nature 1997; 385: 733–6
   PubMed Web of Science ®Google Scholar
• van Kooten C, Gaillard C, Galizzi J P, Hermann P, Fossiez F, Banchereau J, Blanchard D. B cells regulate expression of CD40 ligand on activated T cells by lowering the mRNA level and through the release of soluble CD40. Eur J Immunol 1994; 24: 787–92
   PubMed Web of Science ®Google Scholar
• Dhein J, Walczak H, Baumler C, Debatin K M, Krammer P H. Autocrine T‐cell suicide mediated by APO‐l/(Fas/CD95). Nature 1995; 373: 438–41
   PubMed Web of Science ®Google Scholar
• Dancescu M, Rubio‐Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M. Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl‐2 expression. J Exp Med 1992; 176: 1319–26
   PubMed Web of Science ®Google Scholar
• Foote L C, Marshak‐Rothstein A, Rothstein T L. Tolerant B lymphocytes acquire resistance to Fas‐mediated apoptosis after treatment with interleukin 4 but not after treatment with specific antigen unless a surface immunoglobulin threshold is exceeded. J Exp Med 1998; 187: 847–53
   PubMed Web of Science ®Google Scholar
• Crawford D H, Catovsky D. In vitro activation of leukaemic B cells by interleukin‐4 and antibodies to CD40. Immunology 1993; 80: 40–4
   PubMed Web of Science ®Google Scholar
• Romano M F, Lamberti A, Tassone P, Alfinito F, Costantini S, Chiurazzi F, Defrance T, Bonelli P, Tuccillo F, Turco M C, Venuta S. Triggering of CD40 antigen inhibits fludarabine‐induced apoptosis in B chronic lymphocytic leukemia cells. Blood 1998; 92: 990–5
   PubMed Web of Science ®Google Scholar
• Furman R R, Asgary Z, Mascarenhas J O, Telford W, Liou H ‐C, Schattner E J. Modulation of NF‐kB activity and apoptosis in CLL B cells by CW40 engagement, submitted manuscript
   Google Scholar
• Chandra J, Niemer I, Gilbreath J, Kliche K O, Andreeff M, Freireich E J, Keating M, McConkey D J. Proteasome inhibitors induce apoptosis in glucocorticoid‐resistant chronic lymphocytic leukemic lymphocytes. Blood 1998; 92: 4220–9
   PubMed Web of Science ®Google Scholar
• Yellin M J, Lee J J, Chess L, Lederman S. A human CD4‐ T cell leukemia subclone with contact‐dependent helper function. Journal of Immunology 1991; 147: 3389–95
   PubMed Web of Science ®Google Scholar
• Kato K, Cantwell M J, Sharma S, Kipps T J. Gene Transfer of CD40‐ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 1998; 101: 1133–1141
   PubMed Web of Science ®Google Scholar
• Schattner E J, Mascarenhas J, Bishop J, Yoo D H, Chadburn A, Crow M K, Friedman S M. CD4+ T‐cell induction of Fas‐mediated apoptosis in Burkitt's lymphoma B cells. Blood 1996; 88: 1375–82
   PubMed Web of Science ®Google Scholar
• Shokat K M, Goodnow C C. Antigen‐induced B‐cell death and elimination during germinal‐centre immune responses. Nature 1995; 375: 334–8
   PubMed Web of Science ®Google Scholar
• Pulendran B, Kannourakis G, Noun S, Smith K G, Nossal G J. Soluble antigen can cause enhanced apoptosis of germinal‐centre B cells. Nature 1995; 375: 331–4
   PubMed Web of Science ®Google Scholar
• Chen W, Wang H ‐G, Srinivasula S M, Alnemri E S, Cooper N R. B cell apoptosis triggered by antigen receptor ligation proceeds via a novel caspase‐dependent pathway. J Immunol 1999; 163: 2483–2491
   PubMed Web of Science ®Google Scholar
• Desai‐Mehta A, Lu L, Ramsey‐Goldman R, Datta S K. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996; 97: 2063–73
   PubMed Web of Science ®Google Scholar
• Koshy M, Berger D, Crow M K. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 1996; 98: 826–37
   PubMed Web of Science ®Google Scholar
• Cantwell M, Hua T, Pappas J, Kipps T J. Acquired CD40‐ligand deficiency in chronic lymphocytic leukemia. Nat Med 1997; 3: 984–9
   PubMed Web of Science ®Google Scholar
• Saven A, Piro L D. 2‐Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies. Ann Intern Med 1994; 120: 784–91
   PubMed Web of Science ®Google Scholar
• Tallman M S, Hakimian D. Purine nucleoside analogs: emerging roles in indolent Iymphoproliferative disorders. Blood 1995; 86: 2463–74
   PubMed Web of Science ®Google Scholar
• Damle R N, Wasil T, Fais F, Ghiotto F, Valetto A, Allen S L, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman S M, Schulman P, Vinciguerra V P, Rai K R, Ferrarini M, Chiorazzi N. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840–7
   PubMed Web of Science ®Google Scholar
• Hamblin T J, Davis 2, Gardiner A, Oscier D G, Stevenson F K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–54
   PubMed Web of Science ®Google Scholar
• Rathmell J C, Townsend S E, Xu J C, Flavell R A, Goodnow C C. Expansion or elimination of B cells in vivo: dual roles for CD40‐ and Fas (CD95)‐ligands modulated by the B cell antigen receptor. Cell 1996; 87: 319–29
   PubMed Web of Science ®Google Scholar
• Rothstein T L. Signals and susceptibility to programmed death in B cells. Curr Opin lmmunol 1996; 8: 362–71
   Web of Science ®Google Scholar
• Raman C, Kuo A, Deshane J, Litchfield D W, Kimberly R P. Regulation of casein kinase 2 by direct interaction with cell surface receptor CD5. J Biol Chem 1998; 273: 19183–9
   PubMed Web of Science ®Google Scholar
• Bikah G, Carey J, Ciallella J R, Tarakhovsky A, Bondada S. CD5‐mediated negative regulation of antigen receptor‐induced growth signals in B‐1 B cells. Science 1996; 274: 1906–9
   PubMed Web of Science ®Google Scholar
• Stamenkovic I, Seed B. CD19, the earliest differentiation antigen of the B cell lineage, bears three extracellular immunoglobulin‐like domains and an Epstein‐Ban virus‐related cytoplasmic tail. J Exp Med 1988; 168: 1205–10
   PubMed Web of Science ®Google Scholar
• Carter R H, Fearon D T. CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 1992; 256: 105–7
   PubMed Web of Science ®Google Scholar
• O'Rourke L, Tooze R, Fearon D T. Co‐receptors of B lymphocytes. Cum Opin Immunol 1997; 9: 324–9
   PubMed Web of Science ®Google Scholar
• Buhl A M, Pleiman C M, Rickert R C, Cambier J C. Qualitative regulation of B cell antigen receptor signaling by CD19: selective requirement for PI3‐kinase activation, inositol‐1,4,5‐trisphosphate production and Ca2+ mobilization. J Exp Med 1997; 186: 1897–910
   PubMed Web of Science ®Google Scholar
• Nadler L M, Stashenko P, Hardy R, Schlossman S F. A monoclonal antibody defining a lymphoma‐associated antigen in man. J Immunol 1980; 125: 570–7
   PubMed Web of Science ®Google Scholar
• Tedder T F, Streuli M, Schlossman S F, Saito H. Isolation and structure of a cDNA encoding the B1 (CD20) cell‐surface antigen of human B lymphocytes. Proc Natl Acad Sci USA 1988; 85: 208–12
   PubMed Web of Science ®Google Scholar
• Tefferi A, Bartholmai B J, Witzig T E, Li C Y, Hanson C A, Phyliky R L. Heterogeneity and clinical relevance of the intensity of CD20 and immunoglobulin light‐chain expression in B‐cell chronic lymphocytic leukemia. Am J Clin Pathol 1996; 106: 457–61
   PubMed Web of Science ®Google Scholar
• Camerini D, Walz G, Loenen W A, Borst J, Seed B. The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family. J Immunol 1991; 147: 3165–9
   PubMed Web of Science ®Google Scholar
• Ranheim E A, Cantwell M J, Kipps T J. Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood 1995; 85: 3556–65
   PubMed Web of Science ®Google Scholar
• Lens S M, Tesselaar K, van Oers M H, van Lier R A. Control of lymphocyte function through CD27‐CD70 interactions. Semin Immunol 1998; 10: 491–9
   PubMed Web of Science ®Google Scholar
• Uckun F M, Gajl‐Peczalska K, Myers D E, Jaszcz W, Haissig S, Ledbetter J A. Temporal association of CD40 antigen expression with discrete stages of human B‐cell ontogeny and the efficacy of anti‐CD40 immunotoxins against clonogenic B‐lineage acute lymphoblastic leukemia as well as B‐lineage non‐Hodgkin's lymphoma cells. Blood 1990; 76: 2449–56
   PubMed Web of Science ®Google Scholar
• Goodwin R G, Alderson M R, Smith C A, Armitage R J, Vanden Bos T, Jerzy R, Tough T W, Schoenborn M A, Davis‐Smith T, Hennen K, et al. Molecular and biologicai characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell 1993; 73: 447–56
   PubMed Web of Science ®Google Scholar
• Cerutti A, Trentin L, Zambello R, Sancetta R, Milani A, Tassinari C, Adami F, Agostini C, Semenzato G. The CD5/CD72 receptor system is coexpressed with several functionally relevant counterstructures on human B cells and delivers a critical signaling activity. J Immunol 1996; 157: 1854–62
   PubMed Web of Science ®Google Scholar
• Van de Velde H, von Hoegen I, Luo W, Parnes J R, Thielemans K. The B‐cell surface protein CD72/Lyb‐2 is the ligand for CD5. Nature 1991; 351: 662–5
   PubMed Web of Science ®Google Scholar
• Reth M. The B‐cell antigen receptor complex and co‐receptors. Immunol Today 1995; 16: 310–3
   PubMedGoogle Scholar
• Pleiman C MDDA, Cambier J C. The B‐cell antigen receptor complex: structure and signal transduction. Immunol Today 1994; 15: 393–9
   PubMedGoogle Scholar
• Thompson A A, Talley J A, Do H N, Kagan H L, Kunkel L, Berenson J, Cooper M D, Saxon A, Wall R. Aberrations of the B‐cell receptor B29 (CD79b) gene in chronic lymphocytic leukemia. Blood 1997; 90: 1387–94
   PubMed Web of Science ®Google Scholar
• Yokochi T, Holly R D, Clark E A. B lymphoblast antigen (BB‐1) expressed on Epstein‐Ban virus‐activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas. J Immunol 1982; 128: 823–7
   PubMed Web of Science ®Google Scholar
• Freedman A S, Freeman G, Horowitz J C, Daley J, Nadler L M. B7, a B‐cell‐restricted antigen that identifies pre‐activated B cells. J Immunol 1987; 139: 3260–7
   PubMed Web of Science ®Google Scholar
• Lenschow D J, Walunas T L, Bluestone J A. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14: 233–58
   PubMed Web of Science ®Google Scholar
• Cerutti A, Schaffer A, Shah S, Zan H, Liou H C, Goodwin R G, Casali P. CD30 is a CD40‐inducible molecule that negatively regulates CD40‐mediated immunoglobulin class switching in non‐antigen‐selected human B cells. Immunity 1998; 9: 247–56
   PubMed Web of Science ®Google Scholar
• Trentin L, Zambello R, Agostini C, Enthammer C, Cerutti A, Adami F, Zamboni S, Semenzato G. Expression and regulation of tumor necrosis factor, interleukin‐2, and hematopoietic growth factor receptors in B‐cell chronic lymphocytic leukemia. Blood 1994; 84: 4249–56
   PubMed Web of Science ®Google Scholar
• Lens S M, Tesselaar K, den Drijver B F, van Oers M H, van Lier R A. A dual role for both CD40‐ligand and TNF‐alpha in controlling human B cell death. J Immunol 1996; 156: 507–14
   PubMed Web of Science ®Google Scholar
• Baker S J, Reddy E P. Modulation of life and death by the TNF receptor superfamily. Oncogene 1998; 17: 3261–70
   PubMed Web of Science ®Google Scholar
• Cordingley F T, Bianchi A, Hoffbrand A V, Reittie J E, Heslop H E, Vyakarnam A, Turner M, Meager A, Brenner M K. Tumour necrosis factor as an autocrine tumour growth factor for chronic B‐cell malignancies. Lancet 1988; 1: 969–71
   PubMed Web of Science ®Google Scholar
• Heslop H E, Bianchi A C, Cordingley F T, Turner M, Chandima W, De Mel C P, Hoffbrand A V, Brenner M K. Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders. J Exp Med 1990; 172: 1729–34
   PubMed Web of Science ®Google Scholar
• Jabbar S A, Hoffbrand A V, Gitendra Wickremasinghe R. Regulation of transcription factors NF kappa B and AP‐1 following tumour necrosis factor‐alpha treatment of cells from chronic B cell leukaemia patients. Br J Haematol 1994; 86: 496–504
   PubMed Web of Science ®Google Scholar